Trial Profile
A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Sirexatamab (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 18 Dec 2021 Status changed from recruiting to discontinued.
- 16 Oct 2018 Status changed from not yet recruiting to recruiting.
- 02 Oct 2018 Planned initiation date changed from 31 Aug 2018 to 31 Oct 2018.